Using Recombinant Tissue Plasminogen Activator to Treat Acute Ischemic Stroke in China
Stroke2011Vol. 42(6), pp. 1658–1664
Citations Over TimeTop 10% of 2011 papers
Yilong Wang, Xiaoling Liao, Xingquan Zhao, David Z. Wang, Chunxue Wang, Mai N. Nguyen‐Huynh, Yong Zhou, Liping Liu, Xianwei Wang, Gaifen Liu, Hao Li, Yongjun Wang
Abstract
Approximately 1 in 5 patients with stroke presenting within 3 hours received thrombolytic therapy. The onset-to-needle time, door-to-needle time, and especially imaging-to-needle time were significantly longer than those in developed countries. Reducing prehospital and in-emergency department response time would help increase intravenous rtPA use in China.
Related Papers
- → Decline in Stroke Presentations During COVID-19 Surge(2020)143 cited
- → TeleStroke Units Serving as a Model of Care in Rural Areas(2014)141 cited
- → Stroke Thrombolysis: Having More Time Translates Into Delayed Therapy(2010)43 cited
- Stroke Thrombolysis: Having More Time Translates Into Delayed Therapy(2010)
- → Abstract P552: Characteristics of Acute Stroke Intervention Therapies During Covid-19(2021)